Abstract:Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia disorder associated with lethal arrhythmias. Most CPVT cases are caused by inherited variants in the gene encoding ryanodine receptor type 2 (RYR2). Objective: The goal of this study was to investigate the structure-activity relationship of tetracaine derivatives and to test a lead compound in a mouse model of CPVT. Methods: We synthesized >200 tetracaine derivatives and characterized 11 of those. The effects of these compounds on Ca2+ handling in cardiomyocytes from R176Q/+ mice was tested with confocal microscopy. The effects of lead compound MSV1302 on arrhythmia inducibility and cardiac contractility were tested by programmed electrical stimulation and echocardiography, respectively. Plasma and microsomal stability and cytotoxicity assays were also performed. Results: Ca2+ imaging revealed that 3 of 11 compounds suppressed sarcoplasmic reticulum Ca2+ leak through mutant RyR2. Two compounds selected for further testing exhibited a half-maximal effective concentration of 146 nM (MSV1302) and 49 nM (MSV1406). Whereas neither compound altered baseline electrocardiogram intervals, only MSV1302 suppressed stress- and pacing-induced ventricular tachycardia in vivo in R176Q/+ mice. Echocardiography revealed that the lead compound MSV1302 did not negatively affect cardiac inotropy and chronotropy. Finally, compound MSV1302 did not block INa, ICa,L, or IKr; it exhibited excellent stability in plasma and microsomes, and it was not cytotoxic. Conclusion: Structure-activity relationship studies of second-generation tetracaine derivatives identified lead compound MSV1302 with a favorable pharmacokinetic profile. MSV1302 normalized aberrant RyR2 activity in vitro and in vivo, without altering cardiac inotropy, chronotropy, or off-target effects on other ion channels. This compound may be a strong candidate for future clinical studies to determine its efficacy in CPVT patients.

Optimization of CHARMM force field parameters for ryanodine receptor inhibitory drug dantrolene using FFTK and FFParam

An Advance in the study of ryanodine receptor mutations and malignant hyperthermia

Dantrolene inhibition of ryanodine receptor 1 carrying the severe malignant hyperthermia mutation Y522S visualized by cryo-EM

Structural identification of the RY12 domain of RyR1 as an ADP sensor and the target of the malignant hyperthermia therapeutic dantrolene

A Novel Saline-Soluble, Rapidly-Metabolized RyR1 Inhibitor Rescues Volatile Anesthesia-Induced Death and Environmental Heat Stroke in a Mouse Model Relevant to Malignant Hyperthermia

A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke

Impaired Interaction Between Skeletal Ryanodine Receptors In Malignant Hyperthermia

Ryanodine Receptor Stabilization Therapy Suppresses Ca 2+ -Based Arrhythmias in a Novel Model of Metabolic HFpEF

Structure-activity optimization of ryanodine receptor modulators for the treatment of catecholaminergic polymorphic ventricular tachycardia

Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression

Cardiac Ryanodine Receptor N-terminal Region Biosensors Identify Novel Inhibitors Via FRET-based High-Throughput Screening.

Ryanodine Receptor Stabilization Therapy Suppresses Ca -Based Arrhythmias in a Novel Model of Metabolic HFpEF

RyR2 Binding of an Antiarrhythmic Cyclic Depsipeptide Mapped Using Confocal Fluorescence Lifetime Detection of FRET

Molecular Basis for Allosteric Regulation of the Type 2 Ryanodine Receptor Channel Gating by Key Modulators

Molecular basis for allosteric regulation of the type 2 ryanodine receptor channel gating by key modulators.

Identification of a Dihydropyridine Scaffold That Blocks Ryanodine Receptors.

Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity

Structural basis for ryanodine receptor type 2 leak in heart failure and arrhythmogenic disorders

Chemistry of cation hydration and conduction in a skeletal muscle ryanodine receptor

Chronic Dantrolene Treatment Attenuates Cardiac Dysfunction and Reduces Atrial Fibrillation Inducibility in a Rat Myocardial Infarction Heart Failure Model

Parameterization of a reactive force field using a Monte Carlo algorithm